A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression
Authors
Keywords
Drug metabolism, Metabolomics, Metabolites, Lipid metabolism, Algorithms, Clinical trials, Machine learning algorithms, Biomarkers
Journal
PLoS One
Volume 13, Issue 6, Pages e0198116
Publisher
Public Library of Science (PLoS)
Online
2018-06-06
DOI
10.1371/journal.pone.0198116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolomics in amyotrophic lateral sclerosis: how far can it take us?
- (2016) H. Blasco et al. EUROPEAN JOURNAL OF NEUROLOGY
- Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease
- (2015) Ying-Yong Zhao et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis
- (2015) F. Patin et al. EUROPEAN JOURNAL OF NEUROLOGY
- Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression
- (2015) H. Blasco et al. EUROPEAN JOURNAL OF NEUROLOGY
- Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase
- (2015) Alexandre Henriques et al. HUMAN MOLECULAR GENETICS
- Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis
- (2015) James C. Dodge et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial
- (2015) Muhammad K. Rafiq et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- (2014) H. Blasco et al. CURRENT MEDICINAL CHEMISTRY
- A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
- (2014) T. Lenglet et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
- (2014) Hiroshi Mitsumoto et al. LANCET NEUROLOGY
- A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
- (2014) Michael E. Bozik et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine
- (2014) Adriano Chiò et al. JAMA Neurology
- Nitric oxide and energy metabolism in mammals
- (2013) Zhaolai Dai et al. BIOFACTORS
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS
- (2013) Ettore Beghi et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
- (2010) B.C. Cheah et al. CURRENT MEDICINAL CHEMISTRY
- The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis
- (2009) Yiquan Chen et al. NEUROTOXICITY RESEARCH
- Protective Effects of Riluzole on Dopamine Neurons
- (2003) Alexander Storch et al. JOURNAL OF NEUROCHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started